Axinn is representing Thermo Fisher Scientific Inc., the world leader in serving science, in its $11.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The deal, which was announced on March 3, 2020, will provide Thermo Fisher with the opportunity to leverage its industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. The Axinn antitrust team is led by partners John Harkrider, Michael Keeley, and Mark Alexander, and assisted by James Goldfeier, Varnitha Siva, Chris Brassfield and Patrick Shaw.
Axinn Advises Thermo Fisher on $11.5B Acquisition of QIAGEN
March 3, 2020